GlassScriptPhysician profile
Hua Lin
NPI 1073068516
$2,045.53
in general payments reported to CMS, 2019-2025
14 companies · $284 in 2025
The $284 reported for 2025 was more than what a typical Gerontology (Nurse Practitioner) provider received nationally (typical 2025 total: $180).
See the full distribution for Gerontology (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $111 · 2022: $256 · 2023: $1,026 · 2024: $369 · 2025: $284.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,679.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,679.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $372.10 | 2024-2025 | Auvelity |
| Abbvie INC. | $243.15 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $229.09 | 2021-2023 | Austedo |
| Scpharmaceuticals INC. | $220.45 | 2023-2024 | |
| Neurocrine Biosciences, INC. | $127.25 | 2022 | |
| Sumitomo Pharma America, INC. | $125.40 | 2024 | Myfembree |
| Gilead Sciences, INC. | $123.50 | 2023 | Epclusa |
| Astrazeneca Pharmaceuticals LP | $121.60 | 2023 | Tezspire |
| Ultragenyx Pharmaceutical INC. | $116.28 | 2022 | |
| Merck Sharp & Dohme LLC | $114.05 | 2023 | Verquvo |
| Amgen INC. | $107.51 | 2023 | Repatha |
| Corcept Therapeutics | $99.04 | 2023 | Korlym |
| Glaxosmithkline, LLC. | $31.19 | 2022-2025 | Shingrix, Arexvy |
| Lilly USA, LLC | $14.92 | 2025 | Kisunla |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hua Lin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.